Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks good! :)
STXS hits new low at 0.56- Am I the only one with positiions held in this company?
It appears to be time to start a position in STXS.
~ Monday! $STXS ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $STXS ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=STXS&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=STXS&p=W&b=3&g=0&id=p54550695994
~ Google Finance: http://www.google.com/finance?q=STXS
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=STXS#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=STXS+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=STXS
Finviz: http://finviz.com/quote.ashx?t=STXS
~ BusyStock: http://busystock.com/i.php?s=STXS&v=2
<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=STXS >>>>>>
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
Stereotaxis enters $20 mln royalty financing agreement (STXS) 1.03 : Co announces it has entered into a $20 mln royalty financing agreement with Cowen Healthcare Royalty Partners. The co will receive $15 mln upon satisfaction of closing conditions on or prior to December 5, 2011 and may receive up to an additional $5 mln based on the achievement of certain milestones related to sales of the Stereotaxis robotic navigation system in 2012.
hi everyone
can you tell me what is happing to the Volume of STXS
why does it jump from 100000 shares to 7000 shares?
and why the price still remain the same?
i'm just a small fish try to get to the ocean :)
hope you guy help me to survive
thank you :)
Yes have the same idea, Will wait and watch for now. :)
Yea. I dumped yesterday and will watch for reentry.
I,m watching this one , it looks like it could go below that one dollar range again.
They had an 8-k out that day about a change in debt note or something.
What's tanking stxs today other than the market in general being in the toilet...?
Well I hope it hits $2 today! lol
Now back to STXS :p
More and more insider buys rolling in
More insider buys
SYMBOL: STXS
FILER: ALAFI CHRISTOPHER D
TITLE: Director
DATE TRANSACTION SHARES PRICE VALUE
9/12/11 Purchase 64,468 $1.34 $86,387
OWNERSHIP: 228,286 (Direct) 4,149,598 (Indirect)
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8145036
Did you play it? If you did when I posted, you should be up a cool 35 - 40%
Good suggestion, thanks.
It's in a Form 4 required to be filed by the SEC. You can see it here: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8143073
You can see other financial documents here: http://www.otcmarkets.com/stock/STXS/financials
How do u confirm it?
News
SYMBOL: STXS
FILER: ALAFI CHRISTOPHER D
TITLE: Director
DATE | SHARES | PRICE | VALUE
9/9/11 | 35,532 | $1.33 | $47,258
K. Good luck elswhere. May I suggest ANX
Lookin Good my man!!
From Webcast: Major product coming out in December
iBox/Stickies updated.
Webcast from yesterday's Stifel, Nicolaus & Company Inc. Healthcare Conference
Speaker - Mr. Michael Kaminski CEO
http://www.veracast.com/stifel/healthcare2011/main/player.cfm?eventName=1153_stereo
Results Featured at Europe's Largest Medical Meeting, European Society of
Cardiology
ST. LOUIS--(BUSINESS WIRE)--August 30, 2011--
Stereotaxis, Inc. (NASDAQ: STXS) announced today that the results of the
Study to Obliterate Persistent Ventricular Tachycardia (STOP-VT) was presented
at the European Society of Cardiology (ESC) 2011 Congress held in Paris, France
on Sunday, August 28.
The STOP-VT study is the first-ever, prospective multicenter evaluation of
magnetic navigation for VT ablation. The trial, led by Assoc. Prof. Petr
Neuzil, MD, PhD, Head of Cardiology and Director of the Cardiac Arrhythmia
Service at the Na Homolce Hospital in Prague, Czech Republic was conducted at
four of the world's most prominent arrhythmia treatment centers, including,
Hospital of the University of Pennsylvania, Indiana University School of
Medicine, and Na Homolce Hospital, University of Leipzig. Fifty-three patients
with previous severe heart disease were treated with ventricular tachycardia
(VT) with the Stereotaxis Robotic Ablation System. The acute success rate in
the study was an impressive 94 percent, and no patients suffered a major
complication. The acute success results obtained from the STOP-VT study are
10-15 percent higher than similar published studies using conventional ablation
techniques.
"VT is one of the most challenging arrhythmia facing electrophysiologists due
to complex anatomy, the sensitive nature of ventricular tissue, and potentially
lethal outcomes," said Prof Neuzil. "Catheter ablation of VT, one of the
fastest growing EP procedures globally, requires the delivery of robust lesions
for clinical success. The main advantage of Stereotaxis for treatment of
ventricular tachycardia is the precise mapping and identification of the
critical diseased portions of the heart that allows physicians to perform
ablation in a more effective way. The results of the trial exceeded our
expectations, both in terms of acute outcomes as well as overall safety."
Prof Neuzil presented the STOP-VT data at ESC 2011 on Sunday, August 28. Due
to the significance of the study, Prof Neuzil also discussed the study at an
ESC press conference on Monday, August, 29, "Arrhythmias in the Real World."
"VT is a potentially lethal heart rhythm disorder that requires highly
precise mapping and effective lesion delivery for successful treatment," said
Michael P. Kaminski, President and Chief Executive Officer of Stereotaxis. "The
significant placement of the STOP-VT study results at the world's largest
cardiology meeting reinforces the exceptional value that Stereotaxis brings to
this complex life-saving procedure."
About Stereotaxis www.stereotaxis.com www.odysseyexperience.com
Stereotaxis designs, manufactures and markets an advanced cardiology
instrument control system for use in a hospital's interventional surgical suite
to enhance the treatment of coronary artery disease and arrhythmias. The
Niobe(R) Remote Magnetic Navigation System is designed to enable physicians to
complete more complex interventional procedures by providing image guided
delivery of catheters and guidewires through the blood vessels and chambers of
the heart to treatment sites. This is achieved using computer-controlled,
externally applied magnetic fields that govern the motion of the working tip of
the catheter or guidewire, resulting in improved navigation, shorter procedure
time and reduced x-ray exposure.
Stereotaxis' Odyssey(TM) portfolio of products provides an innovative
enterprise solution for integrating, recording and networking interventional
lab information within hospitals and around the world. Odyssey(TM) Vision
integrates data for magnetic and standard interventional labs, enhancing the
physician workflow through a consolidated display of multiple systems and
eliminating the challenge of interacting simultaneously with many separate
diagnostic systems. Odyssey(TM) Enterprise Cinema then captures a complete
record of synchronized procedure data that can be viewed live or from a
comprehensive archive of cases performed. Odyssey(TM) then enables hospitals to
efficiently share live and recorded clinical data anywhere around the world to
maximize referrals and promote collaboration.
The core components of the Stereotaxis systems have received regulatory
clearance in the U.S., Europe, Canada and elsewhere. For more information,
please visit www.stereotaxis.com and www.odysseyexperience.com.
This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, continued acceptance of the
Company's products in the marketplace, the effect of global economic conditions
on the ability and willingness of customers to purchase our systems and the
timing of such purchases, competitive factors, changes resulting from the
recently enacted healthcare reform in the U.S., including changes in government
reimbursement procedures, dependence upon third-party vendors, timing of
regulatory approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By making these
forward-looking statements, the Company undertakes no obligation to update
these statements for revisions or changes after the date of this release. There
can be no assurance that the Company will recognize revenue related to its
purchase orders and other commitments in any particular period or at all
because some of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In addition, these
orders and commitments may be revised, modified, delayed or canceled, either by
their express terms, as a result of negotiations, or by overall project changes
or delays.
CONTACT: Company Contact:
Stereotaxis, Inc.
Rod McCrimmon,
314-678-6100
Rod.McCrimmon@stereotaxis.com
or
Investor
Contact:
Stereotaxis, Inc.
Frank Cheng,
314-678-6100
Frank.Cheng@stereotaxis.com
or
Media Contact:
Schwartz
Communications
Krystin Hayward/Kirsten Fallon,
781-684-0770
Stereotaxis@schwartzcomm.com
SOURCE: Stereotaxis, Inc.
Copyright Business Wire 2011
(END) Dow Jones Newswires
08-30-11 1724ET
17:24 083011
SOURCE: Form 4
ISSUER: STEREOTAXIS INC
SYMBOL: STXS
FILER: KAMINSKI MICHAEL P
TITLE: Chief Executive Officer
DATE TRANSACTION SHARES PRICE VALUE
9/1/11 Purchase 10,400 $1.43 $14,872
OWNERSHIP: 125,567 (Direct) 3,700 (Indirect)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
(END) Dow Jones Newswires
09-06-11 1209ET
12:09 090611
You are in scootter82! ... Let's Do This!!!
.
Holding up really well even with all the sells going through - http://ih.advfn.com/p.php?pid=trades&symbol=STXS
No problem. Wow looking great today. Nice move up!
Just messin with ya. 1.45 now! The real resistance will be int he 1.65 area. That's what we need to surpass.
Oh no I am as positive as the next guy but I have seen the pps hit the $1.43 and bounce right back. I am not selling because I think this will do very well longer term.
Well with that attitude, ;)
Chart looks good to me. Think we'll do pretty good soon
$1.43 is the wall that seems to be impossible to break.
Cause It is coming to 2$ easily this month
Guys will it get to up to $4 after 2 months
Well we've cracked the $1.40, now we need to hold it!
Yeah sure is. Like I said though the $1.40 area is tough to break so once we do that I think we are back in business. GLTY. Last post for me today. DO not be surprised if it opens red again. This stock seems to open red and recovery at the end of the day. You can day trade this from open to close pretty easily.
Followers
|
30
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
951
|
Created
|
03/01/11
|
Type
|
Free
|
Moderators |
http://www.stereotaxis.com/
Stereotaxis, Inc. is engaged in designing , manufacturing and marketing the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital's interventional surgical suite, or interventional lab. The Epoch Solution is consists of the Niobe ES Robotic Magnetic Navigation System (Niobe ES system), Odyssey Information Management Solution (Odyssey Solution), and the Vdrive Robotic Navigation System. The Company has alliances with Siemens, Philips and Biosense Webster. The Company has regulatory clearance, licensing and/or CE Mark approvals to market the Niobe Robotic Magnetic Navigation System, the Cardiodrive automated catheter advancement system, and various disposable interventional devices in the United States, Canada, Europe, China and various other countries.
Niobe ES Robotic Magnetic Navigation System
The Company’s Niobe ES robotic system provides the physician with remote digital instrument control through point and click computer mouse control, in combination with image integration and three dimensional (3D) reconstruction. It can be operated either from beside the patient table, as in traditional interventional procedures, or from a room adjacent to the patient and outside the x-ray fluoroscopy field. The Niobe ES robotic system allows the operator to navigate disposable interventional devices to the treatment site through paths in the blood vessels and chambers of the heart to deliver treatment by using computer controlled, externally applied magnetic fields to directly govern the motion of the working tip of these devices, each of which has a magnetically sensitive tip that predictably responds to magnetic fields generated by its system.
The Company has integrated its Niobe ES robotic system with Siemens’ and with Philips’ digital x-ray fluoroscopy systems. In addition, it have integrated the Niobe ES robotic system with Biosense Webster’s 3D catheter location sensing technology to provide real-time information as to the 3D location of the working tip of the instrument, and with Biosense Webster’s ablation tip technology. The components of the Niobe ES robotic system are Niobe Robotic Magnetic Navigation System, which utilizes two permanent magnets mounted on articulating and pivoting arms that are enclosed within a stationary housing, with one magnet on either side of the patient table. The Niobe ES robotic system is indicated for use in cardiac, peripheral and neurovascular applications and Cardiodrive Automated Catheter Advancement System, as the physician conducts the procedure from the adjacent control room, the Cardiodrive or QuikCAS automated catheter advancement systems are used to remotely advance and retract the electrophysiology catheter in the patient’s heart while the Niobe magnets steer the working tip of the device.
Odyssey Solution
The Odyssey Solution offers a fully integrated, real-time information solution to manage, control, record and share procedures across networks or around the world. Through the use of a single mouse and keyboard, the Odyssey Solution allows the user to command multiple systems in the lab from a single point of control. In addition, the Odyssey Solution acquires a real-time, remote view of the lab capturing synchronized procedure data for review of important events during cases. The Odyssey Solution enables physicians to access recorded cases and create snapshots following procedures for enhanced clinical reporting, auditing and presentation. The Odyssey Solution enables physicians to establish a master archive of procedures performed in the lab providing a tool for training new staff on the standard practices. The Odyssey Solution further enables procedures to be observed remotely around the world with Internet access over a hospital VPN even wirelessly using a standard laptop or Windows tablet computer.
Vdrive Robotic Navigation System
The Vdrive Robotic Navigation System and Niobe ES robotic system provide independent remote manipulation of diagnostic catheters and magnetic ablation catheters in a single interface. The Vdrive Robotic Navigation System provides navigation and stability for diagnostic and ablation devices designed with features to assist in the delivery of better ablations. Features include complementing the Niobe ES control of catheters for fully remote procedures; enabling fully remote, single operator workflow; and providing robotic control of diagnostic devices independent of magnetic navigation. The Vdrive Duo system is an optional expansion of the Vdrive hardware that allows control of the V-loop device and either V-CAS or V-CAS Deflect devices in the same procedure, with a single user interface.
Disposables and Other Accessories
The Company’s Niobe system is designed to use a toolkit of disposable interventional devices. The toolkit consists of Cardiodrive or QuikCAS, which is automated catheter advancement disposables designed to provide e remote advancement of electrophysiology catheters; Cronus, Assert, Titan and Pegasus coronary guidewires, which is designed for use in interventional cardiology procedures for the introduction and placement of over-the-wire therapeutic devices, such as stents and angioplasty balloons; and Biosense Webster’s CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL and CELSIUS RMT THERMOCOOL Irrigated Tip Diagnostic/Ablation Steerable Tip Catheters co-developed by Biosense Webster and Stereotaxis.
In addition to the Vdrive and Vdrive Duo systems, The Company also manufacture and market various disposable components, including V-CAS catheter advancement system that controls both the magnetic catheter body and a standard fixed-curve sheath; V-loop circular catheter manipulator, which allows the user to control certain circular mapping catheters, such as Biosense Webster’s LASSO2515 or LASSO2515 NAV Circular Mapping Catheter, and advance, retract, rotate, deflect and adjust loop radius, all without leaving the control room and V-CAS Deflect fully integrated catheter advancement system with a robotic deflectable sheath for
Contact Information |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |